Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
about
Angiotensin receptors, autoimmunity, and preeclampsiaRecent advances in central cardiovascular control: sex, ROS, gas and inflammationPreeclampsia: long-term consequences for vascular healthThe use of novel diagnostics to individualize immunosuppression following transplantationVascular endothelium as a target of immune response in renal transplant rejectionAngiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyondEffector mechanisms of rejectionUnraveling the Role of Allo-Antibodies and Transplant InjuryAntibody Subclass Repertoire and Graft Outcome Following Solid Organ TransplantationImmune-mediated vascular injury and dysfunction in transplant arteriosclerosisImmunity in arterial hypertension: associations or causalities?HIF-1α signaling by airway epithelial cell K-α1-tubulin: role in fibrosis and chronic rejection of human lung allograftsPotential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertensionDe novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized ratsHypertension in the Pediatric Kidney Transplant RecipientB-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans.Mechanisms of Autoantibody-Induced Pathology.Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patientsLigand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss.Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation.The generation and maintenance of serum alloantibody.Non-MHC antigenic targets of the humoral immune response in transplantationPreeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.The immunological basis of hypertensionRole of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts.Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.Antibodies reactive to non-HLA antigens in transplant glomerulopathyPerindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptorHypertension in response to placental ischemia during pregnancy: role of B lymphocytes.Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients.Autoimmunity: an underlying factor in the pathogenesis of hypertension.Emerging role of B cells in chronic allograft dysfunction.Late kidney allograft loss: what we know about it, and what we can do about it
P2860
Q24605647-876280F5-0B10-4C31-96DD-6252137B73D6Q26752442-05792886-5BF0-4956-B863-236D1A9D30CFQ26800272-4009867A-B4DD-4FEC-B17D-68377EC2E911Q26864686-524E2CB7-0682-4046-B316-1D98DA6EAAB9Q27024077-D8C0B7FA-D8F9-452D-95CD-45D20A9B2DF3Q27027039-F5AA2F17-1EAD-4014-ADD3-F7887890CCBCQ27027082-96534364-1FBA-4F47-913D-C6036D3B7EF6Q28069336-39EAAC32-6083-451B-BB17-05B05BCB816AQ28076193-CAE84D1D-E303-456C-AB40-22E588AF66BBQ28084366-20F967FC-57AB-4185-9956-CF910D937B71Q28087302-DEF2C529-DD49-4D29-B2D4-CC4B9EBFA0B3Q28395914-354DA422-6FFE-4156-94DB-0BDB9AED5A84Q28575913-04548979-73FD-4239-8344-CBE646256E2FQ33551885-F3E623DA-645F-4DBE-9E6E-20BA1B5E3AABQ33568986-75212EAB-A8BD-4F04-BB58-D3333F1D1908Q33577570-C8EE6083-C139-4C4F-9769-04EB761F45D6Q33619380-96776758-198D-4A7D-8FAB-09937B3D2E0FQ33723769-6FD0F3E5-4F07-43CE-903E-F0E5836A666AQ33740580-749D2B5A-3E45-432D-B1FB-45FDBDAFB13DQ33765684-91AD2DCF-37E6-4100-8485-77CF8A9CF761Q33855316-BD4FCFB0-93BB-4BDB-9E5F-88698D917D9EQ33998148-0BE12E2A-5FCE-4F7C-900F-682383861610Q34079646-67188178-1E2E-4C88-800D-0206753365C5Q34106158-3E9A68C8-01B4-4404-BC34-4985DAE2C01EQ34259047-5BF0C763-781C-4F89-8A04-5C008FFB0D91Q34453242-A713721A-835C-4F2B-80FE-31E06CA3C81FQ34581918-1D6B9B28-881E-46D5-A950-86F6D63FD0E6Q34595998-3880C2A0-290E-452D-8D6B-A51DF991B810Q34683745-B053BFCF-A6E5-443A-B9AC-3A21AFD48A7EQ34785813-EC254040-5AC9-4DB9-9C7A-A25020A11A65Q34841849-95C37EE0-ED3A-468B-BEFF-2D7BE79442AEQ34970022-70345797-A8C9-46F5-A8DB-DC1E1C807430Q34978758-780DB9F1-0E3B-4BBB-85F8-D889D1FB8307Q35012455-60824606-F20F-4886-810E-84CCF396351CQ35029497-D35C1976-EF63-4220-9707-61B46EF18B75Q35029700-AFEDCD69-5087-440E-B93F-6DA3CD117F78Q35091339-82E99027-0586-450C-B1C9-58A4C2B8EADCQ35116086-E76AA4FF-5489-4D7D-9CC9-0A486541804EQ35124576-2EDA6950-27AA-4F6F-A14F-C8B2C5640A69Q35153318-1981241B-A216-4313-96DD-55B43DAE949C
P2860
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@en
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@nl
type
label
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@en
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@nl
prefLabel
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@en
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@nl
P2093
P50
P921
P356
P1476
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
@en
P2093
Birgit Rudolph
Constanze Schönemann
Diana Eckert
Dominik N Müller
Duska Dragun
Hans-Hellmut Neumayer
Istvan Mazak
Jan Hinrich Bräsen
Johan Hoebeke
Klemens Budde
P304
P356
10.1056/NEJMOA035717
P407
P577
2005-02-01T00:00:00Z